Cargando…

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

OBJECTIVE: To examine the long-term impact of early treatment initiation of interferon beta-1b (IFNB1b, Betaferon/Betaseron) in patients with a first event suggestive of multiple sclerosis (MS). METHODS: In the original placebo-controlled phase of BENEFIT, patients were randomised to IFNB1b 250 μg o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edan, G, Kappos, L, Montalbán, X, Polman, C H, Freedman, M S, Hartung, H-P, Miller, D, Barkhof, F, Herrmann, J, Lanius, V, Stemper, B, Pohl, C, Sandbrink, R, Pleimes, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215285/ https://www.ncbi.nlm.nih.gov/pubmed/24218527 http://dx.doi.org/10.1136/jnnp-2013-306222

Ejemplares similares

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
por: Penner, Iris-Katharina, et al.
Publicado: (2012)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis
por: Montalban, Xavier, et al.
Publicado: (2023)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2020)

TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
por: López-Gómez, Carlos, et al.
Publicado: (2016)

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015)

Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
por: Colato, Elisa, et al.
Publicado: (2021)

Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS
por: Duan, Yunyun, et al.
Publicado: (2021)

Automated brain volumetrics in multiple sclerosis: a step closer to clinical application
por: Wang, C, et al.
Publicado: (2016)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
por: Kappos, Ludwig, et al.
Publicado: (2016)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018)

Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community
por: Minnema, L. A., et al.
Publicado: (2020)

Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
por: McGuigan, C, et al.
Publicado: (2016)

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis
por: Freedman, MS, et al.
Publicado: (2012)

Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway
por: Grytten, N, et al.
Publicado: (2016)

The “Treatise on the spleen and stomach” (Pí Wèi Lùn) as the first record of multiple sclerosis in the medical literature – A hypothesis based on the analysis of clinical presentation and herbal medicine
por: Fuzimoto, Andréa D., et al.
Publicado: (2020)

T cell composition and polygenic multiple sclerosis risk: A population‐based study in children
por: de Mol, Casper L., et al.
Publicado: (2021)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
por: van de Pavert, Steven H P, et al.
Publicado: (2016)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

First‐line therapies in late‐onset multiple sclerosis: An Italian registry study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Brain age as a surrogate marker for cognitive performance in multiple sclerosis
por: Denissen, Stijn, et al.
Publicado: (2022)

Re-evaluating the treatment of acute optic neuritis
por: Bennett, Jeffrey L, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t3qpk05t5m8up1uusvr63topvd